128 related articles for article (PubMed ID: 26976997)
1. Prognostic Value of Anti-Müllerian Hormone and Inhibin B in Patients with Premenopausal Hormone Receptor-positive Breast Cancer.
Kim HA; Seong MK; Kim JH; Kim YG; Choi HS; Kim JS; Park IC; Jin HO; Lee JK; Noh WC
Anticancer Res; 2016 Mar; 36(3):1051-7. PubMed ID: 26976997
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
Xue C; Wei W; Sun P; Zheng W; Diao X; Xu F; Huang J; An X; Xia W; Hong R; Jiang K; Huang R; Yuan Z; Wang S; Li A; Zou R; Shi Y
Breast Cancer Res Treat; 2019 Feb; 173(3):619-628. PubMed ID: 30392113
[TBL] [Abstract][Full Text] [Related]
3. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.
Furlanetto J; Marmé F; Seiler S; Thode C; Untch M; Schmatloch S; Schneeweiss A; Bassy M; Fasching PA; Strik D; Stickeler E; Schem C; Karn T; Grischke EM; Denkert C; van Mackelenbergh M; Müller V; Nekljudova V; Loibl S
Eur J Cancer; 2021 Jul; 152():193-203. PubMed ID: 34116270
[TBL] [Abstract][Full Text] [Related]
5. Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
Henry NL; Xia R; Schott AF; McConnell D; Banerjee M; Hayes DF
Oncologist; 2014 Jan; 19(1):68-74. PubMed ID: 24319018
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.
Anders C; Marcom PK; Peterson B; Gu L; Unruhe S; Welch R; Lyons P; Behera M; Copland S; Kimmick G; Shaw H; Snyder S; Antenos M; Woodruff T; Blackwell K
Cancer Invest; 2008; 26(3):286-95. PubMed ID: 18317970
[TBL] [Abstract][Full Text] [Related]
7. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
[TBL] [Abstract][Full Text] [Related]
9. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.
Partridge AH; Ruddy KJ; Gelber S; Schapira L; Abusief M; Meyer M; Ginsburg E
Fertil Steril; 2010 Jul; 94(2):638-44. PubMed ID: 19409543
[TBL] [Abstract][Full Text] [Related]
10. Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
Trapp E; Steidl J; Rack B; Kupka MS; Andergassen U; Jückstock J; Kurt A; Vilsmaier T; de Gregorio A; de Gregorio N; Tzschaschel M; Lato C; Polasik A; Tesch H; Schneeweiss A; Beckmann MW; Fasching PA; Janni W; Müller V
Breast; 2017 Oct; 35():130-135. PubMed ID: 28732324
[TBL] [Abstract][Full Text] [Related]
11. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
[TBL] [Abstract][Full Text] [Related]
12. The clinical utility of serum anti-Müllerian hormone in the follow-up of ovarian adult-type granulosa cell tumors--A comparative study with inhibin B.
Färkkilä A; Koskela S; Bryk S; Alfthan H; Bützow R; Leminen A; Puistola U; Tapanainen JS; Heikinheimo M; Anttonen M; Unkila-Kallio L
Int J Cancer; 2015 Oct; 137(7):1661-71. PubMed ID: 25808251
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
14. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
15. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
Torrisi R; Bagnardi V; Rotmensz N; Scarano E; Iorfida M; Veronesi P; Luini A; Viale G; Santoro A; Colleoni M; Goldhirsch A
Breast Cancer Res Treat; 2011 Apr; 126(2):431-41. PubMed ID: 21221766
[TBL] [Abstract][Full Text] [Related]
16. Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank.
Irvin SR; Weiderpass E; Stanczyk FZ; Brinton LA; Trabert B; Langseth H; Wentzensen N
Cancer Epidemiol Biomarkers Prev; 2020 Mar; 29(3):636-642. PubMed ID: 31932414
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
Anderson RA; Cameron DA
J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
[TBL] [Abstract][Full Text] [Related]
18. Ovarian reserve in premenopausal women with breast cancer.
Zong X; Yu Y; Chen W; Zong W; Yang H; Chen X
Breast; 2022 Aug; 64():143-150. PubMed ID: 35691250
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer.
Koga C; Akiyoshi S; Ishida M; Nakamura Y; Ohno S; Tokunaga E
Breast Cancer; 2017 Sep; 24(5):714-719. PubMed ID: 28243992
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of serum anti-mullerian hormone and inhibin B in prediction of ovarian response in patients with polycystic ovary syndrome.
Zhang F; Liu XL; Rong N; Huang XW
J Huazhong Univ Sci Technolog Med Sci; 2017 Feb; 37(1):70-73. PubMed ID: 28224431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]